Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Cable-Tie Hardware Installs Permanently Without Screws, Adhesives

December 10, 2010 6:16 am | PennEngineering | Product Releases | Comments

PEM self-clinching cable tie-mounts and hooks provide secure attachment points for mounting wires and cables to electronic chassis or enclosures.

Miniaturized Positioning Controller Developed for CANopen Network

December 10, 2010 6:12 am | Maxon Precision Motors, Inc. | Product Releases | Comments

maxon’s EPOS2 24/2 was developed specifically for commanding and controlling in the CANopen network. USB and RS232 are available as further communication interfaces.

Boston Micromachines, Bridger Photonics sign consulting deal

December 10, 2010 5:33 am | by I-Micronews | News | Comments

Boston Micromachines Corp. (BMC) announced Monday that it has signed a consulting agreement with Bridger Photonics Inc. to quantitatively assess a new MEMS membrane deformable mirror design using BMC?s facilities.

Advertisement

Mylan Receives Approval for Generic Version of Adalat® CC Tablets

December 10, 2010 5:32 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, Dec. 10, 2010 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP,...

TOPICS:

Tomophase OCTIS(TM) Receives FDA 510(K) Clearance to Market

December 10, 2010 5:31 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 10, 2010 /- Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS. Tomophase is a leader in the development of OCT...

TOPICS:

Combination Therapy Reduced HER2-positive Breast Cancers

December 10, 2010 4:35 am | by AACR | News | Comments

SAN ANTONIO - A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held...

TOPICS:

Pertuzumab and Trastuzumab Combination Improved Efficacy for Women With HER2-positive Breast Cancer

December 10, 2010 4:34 am | by AACR | News | Comments

SAN ANTONIO - The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

TOPICS:

Phase III Study Compared Neoadjuvant Therapy with Lapatinib or Trastuzumab for Early Breast Cancer

December 10, 2010 4:34 am | by AACR | News | Comments

SAN ANTONIO - Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer...

TOPICS:
Advertisement

NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SANTA CLARA, Calif., Dec. 10, 2010 /- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, today presented the results from a blinded drug safety study conducted by the Cardiac Safety Research Consortium (CSRC) to evaluate the performance of...

TOPICS:

Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Dec. 10, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial...

TOPICS:

HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock

December 10, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 10, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf...

TOPICS:

A Magnetic Shortcut to Clinical Trials

December 9, 2010 8:34 pm | by Massachusetts Institute of Technology | News | Comments

Finding effective drug dosages using MRI could accelerate drug development.

TOPICS:

Buprenorphine treatment produces improved outcome for babies born addicted

December 9, 2010 4:37 pm | by EurekAlert | News | Comments

(Vanderbilt University Medical Center) Babies born into the world addicted to drugs because of their mother's dependence on pain medication, or opioids, may be weaned off the substance more comfortably, with a shorter hospital stay and at a reduced cost, if the mother receives a...

TOPICS:

Covidien Receives FDA 510(k) Clearance for the iDrive(TM) Powered Stapling System

December 9, 2010 4:35 pm | by Covidien | News | Comments

Company's first powered stapling system provides precision, control, access and visibility during open surgical procedures NORTH HAVEN, Conn., Dec 02, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in surgical...

TOPICS:

Covidien Announces the Launch of Three New Platforms for its Puritan Bennett(TM) 840 Ventilators

December 9, 2010 4:34 pm | by Covidien | News | Comments

Puritan Bennett(TM) 840 Neonatal, Universal and Pediatric-Adult Ventilators Deliver Comprehensive Ventilation to a Broad Range of Patients BOULDER, Colo., Dec 09, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading